LG Life Sciences to Market Thymitaq® in Republic of Korea
Business Review Editor
Abstract
EXIMIAS Pharmaceutical granted LG Life Sciences the distribution rights to Thymitaq in Korea. Thymitaq is an inhibitor of the enzyme thymidylate synthase and potential anticancer drug.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.